TME Pharma Showcases NOX-A12 Research at Upcoming Conference
BERLIN -- TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing innovative therapies for cancer, has some exciting news. An abstract featuring significant NOX-A12 findings from preclinical studies by the U.S. National Cancer Institute (NCI) has been selected for presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting.
Event Overview
The SNO Annual Meeting is recognized as the largest neuro-oncology conference globally, drawing a diverse audience from over 40 countries, including top researchers and clinician scientists. This important event serves as a premier platform for sharing the latest advancements and insights in neuro-oncology research and treatment. TME Pharma will actively engage with industry leaders during the conference, which is scheduled for November 21-24, 2024.
Poster Presentation Details
At the meeting, there will be a poster presentation that focuses on a study entitled: Potentiating the efficacy of immune checkpoint inhibitors in glioblastoma by inhibition of CXCL12. Dr. Chen Cam-El Makranz, a Neuro-Oncology Research Fellow at the NCI, will present the poster.
Here are the specifics of the presentation:
- Session: Poster Session, Poster number EXTH12
- Date and Time: 7:30-9:30 PM CDT, Friday, November 22, 2024
The full abstract is anticipated to be published in the SNO’s official journal, Neuro-Oncology, on November 11, 2024, and the materials will be accessible on the TME Pharma website after the conference.
About NOX-A12
NOX-A12 is a specialized CXCL12 inhibitor created by TME Pharma, specifically designed to target the tumor microenvironment (TME). This innovative therapy aims to fight aggressive cancers, such as glioblastoma, which is a particularly deadly form of brain cancer. Research on NOX-A12 looks to enhance the effectiveness of current treatment approaches by neutralizing tumor defenses and improving patient responses to therapies.
Clinical Trials and Achievements
TME Pharma's ongoing GLORIA Phase 1/2 trial is examining NOX-A12 in newly diagnosed brain cancer patients who might not respond well to standard chemotherapy treatments. Preliminary results from studies involving NOX-A12 combined with radiotherapy show encouraging tumor reductions and responses. Other aspects of the trial are investigating NOX-A12's safety and effectiveness when paired with various additional treatments, with the goal of finding the best therapeutic options for patients.
Furthermore, TME Pharma has received FDA fast-track designation for NOX-A12 in conjunction with radiotherapy and bevacizumab for glioblastoma treatment. This fast-track status highlights the company’s dedication to improving care for patients facing this difficult cancer.
About TME Pharma
TME Pharma takes an innovative approach to oncology by focusing on modifying the cancer immunity cycle through its drug development pipeline. By breaking down the tumor's protective barriers, the company seeks to strengthen immune responses and improve treatment outcomes. They are also exploring other drug candidates, like NOX-E36, which targets the innate immune system to treat various solid tumors.
Looking Ahead
As TME Pharma readies itself for the SNO Annual Meeting, the company is still enhancing its clinical initiatives and partnerships. Their collaboration with MSD/Merck is aimed at advancing NOX-A12 research in combination with existing treatments for patients fighting metastatic pancreatic cancer.
This combination of research efforts and collaboration underscores TME Pharma's enduring commitment to expanding the horizons of cancer treatment. With ongoing studies and presentations at key conferences, they continue to aim for new ways to enhance therapy.
Frequently Asked Questions
What is the main focus of TME Pharma?
TME Pharma is committed to developing innovative therapies that target the tumor microenvironment, aiming to treat aggressive cancers.
What is NOX-A12?
NOX-A12 is a CXCL12 inhibitor created to enhance the effectiveness of existing cancer treatments by specifically targeting the tumor microenvironment.
When and where will the SNO Annual Meeting take place?
The SNO Annual Meeting will be held from November 21-24, 2024, at a venue in Houston.
Who is presenting the poster at the SNO Annual Meeting?
The poster on NOX-A12 will be presented by Dr. Chen Cam-El Makranz, a Neuro-Oncology Research Fellow from the NCI.
What does the FDA fast-track designation for NOX-A12 mean?
The FDA fast-track designation speeds up the development and review process for NOX-A12, recognizing it as a promising treatment option for glioblastoma.
